First Patient Dosed in Phase I Clinical Trial Using RoosterBio’s Cellular Starting Materials

FREDERICK, Md., March 6 (Korea Bizwire) — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today a significant milestone in the regenerative medicine field with the dosing of the first patient using its innovative cellular starting materials. The patient has been treated by RoosterBio’s [...]